Moses Goddard

Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA.

CytoSolv, Inc. develops proprietary technology to address wound healing. Its technology involves a mixture of wound-healing factors derived from porcine choroid plexus (CP), a key component of the blood brain barrier, which naturally secretes a variety of proteins into the cerebrospinal fluid responsible for growth, differentiation, nurturing and maintenance of the healing function. The company was founded by Moses Goddard and Christopher D. Thanos in 2009 and is headquartered in Providence, RI.